Next Article in Journal
Disease Resurgence, Production Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a Need for a New Yellow Fever Vaccine?
Previous Article in Journal
Parenterally Administered P24-VP8* Nanoparticle Vaccine Conferred Strong Protection against Rotavirus Diarrhea and Virus Shedding in Gnotobiotic Pigs
Open AccessArticle

Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B

1
Infectious Diseases Department, Hospital Clínic-HIVACAT, IDIBAPS, University of Barcelona, 08036 Barcelona, Spain
2
Infectious Diseases Unit, Parc Sanitari Sant Joan de Deu, 08830 Sant Boi de Llobregat, Spain
3
Irsicaixa AIDS Research Institute-HIVACAT, Hospital Germans Trias i Pujol, 08916 Badalona, Spain
4
Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CNB-CSIC), Campus de Cantoblanco, 28049 Madrid, Spain
5
Clinical Trial Unit, Hospital Clínic, 08036 Barcelona, Spain
6
Infectious Diseases Department, Hospital Gregorio Marañón, 28009 Madrid, Spain
7
Retrovirology and Viral Immunopathology, AIDS Research Group, IDIBAPS, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
*
Author to whom correspondence should be addressed.
These authors contributed equally.
Vaccines 2019, 7(4), 178; https://doi.org/10.3390/vaccines7040178
Received: 22 October 2019 / Revised: 1 November 2019 / Accepted: 4 November 2019 / Published: 7 November 2019
(This article belongs to the Section HIV Vaccines)
There are few studies comparing the safety and immunogenicity of the same HIV immunogen in healthy volunteers and HIV-infected individuals. We analyzed demographics, adverse events (AEs), and immunogenicity against vaccinia virus in preventive (RISVAC02, n = 24 low-risk HIV-negative volunteers) and therapeutic (RISVAC03, n = 20 successfully treated chronically HIV-1-infected individuals) vaccine phase-I clinical trials that were performed with the same design and the same immunogen (modified vaccinia virus Ankara-B: MVA-B). Total AEs were significantly higher in HIV-infected patients (mean AEs/patient 6.6 vs. 12.8 (p < 0.01)). Conversely, the number of AEs related to vaccination (AEsRV) was similar between both groups. No grade III or IV AEsRV were observed in either clinical trial. Regarding the immunogenicity, the proportion of anti-vaccinia virus antibody responders was similar in both studies. Conversely, the magnitude of response was significantly higher in HIV-infected patients (median binding antibodies at w8 267 vs. 1600 U/mL (p = 0.002) and at w18 666 vs. 3200 U/mL (p = 0.003)). There was also a trend towards higher anti-vaccinia virus neutralizing activity in HIV-infected individuals (proportion of responders 37% vs. 63% (p = 0.09); median IC50 32 vs. 64 (p = 0.054)). This study confirms the safety of MVA-B independent of HIV serostatus. HIV-infected patients showed higher immune responses against vaccinia virus. View Full-Text
Keywords: vaccine; HIV-1; preventive; therapeutic; MVA-B vaccine; HIV-1; preventive; therapeutic; MVA-B
Show Figures

Figure 1

MDPI and ACS Style

Couto, E.; Diaz-Brito, V.; Mothe, B.; Guardo, A.C.; Fernandez, I.; Ugarte, A.; Etcheverry, F.; Gómez, C.E.; Esteban, M.; Pich, J.; Arnaiz, J.A.; López Bernaldo de Quirós, J.C.; Brander, C.; Plana, M.; García, F.; Leal, L. Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B. Vaccines 2019, 7, 178.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop